JP2012528199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528199A5 JP2012528199A5 JP2012513311A JP2012513311A JP2012528199A5 JP 2012528199 A5 JP2012528199 A5 JP 2012528199A5 JP 2012513311 A JP2012513311 A JP 2012513311A JP 2012513311 A JP2012513311 A JP 2012513311A JP 2012528199 A5 JP2012528199 A5 JP 2012528199A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- suspending agent
- metered dose
- dose inhaler
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 32
- 239000000375 suspending agent Substances 0.000 claims 17
- 229940071648 Metered Dose Inhaler Drugs 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 239000000725 suspension Substances 0.000 claims 11
- 239000012190 activator Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 claims 7
- 239000010419 fine particle Substances 0.000 claims 7
- 229960002848 formoterol Drugs 0.000 claims 7
- 229940015042 Glycopyrrolate Drugs 0.000 claims 5
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 5
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 206010047139 Vasoconstriction Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 230000002685 pulmonary Effects 0.000 claims 4
- 230000025033 vasoconstriction Effects 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 2
- 229960004436 Budesonide Drugs 0.000 claims 2
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N Ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 2
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 229960001664 Mometasone Drugs 0.000 claims 2
- 208000004361 Obstructive Lung Disease Diseases 0.000 claims 2
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 2
- 206010038687 Respiratory distress Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 230000001133 acceleration Effects 0.000 claims 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 229960003728 ciclesonide Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 201000003883 cystic fibrosis Diseases 0.000 claims 2
- -1 dexpyronium Chemical compound 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 230000005713 exacerbation Effects 0.000 claims 2
- 229960002714 fluticasone Drugs 0.000 claims 2
- 229940021598 formoterol and budesonide Drugs 0.000 claims 2
- 200000000018 inflammatory disease Diseases 0.000 claims 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 2
- 230000000414 obstructive Effects 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229930006677 A03BA01 - Atropine Natural products 0.000 claims 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 1
- 229960000396 Atropine Drugs 0.000 claims 1
- 229940092705 Beclomethasone Drugs 0.000 claims 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N Benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims 1
- 229940093239 Benztropine Drugs 0.000 claims 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N Chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N Dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims 1
- 229960004993 Dimenhydrinate Drugs 0.000 claims 1
- LSLYOANBFKQKPT-UHFFFAOYSA-N Fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 claims 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N Flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 claims 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 1
- 229960001888 Ipratropium Drugs 0.000 claims 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N Pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 229960000195 Terbutaline Drugs 0.000 claims 1
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 claims 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 claims 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229960001081 benzatropine Drugs 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229960002179 ephedrine Drugs 0.000 claims 1
- 229960001022 fenoterol Drugs 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- 229940021608 formoterol and mometasone Drugs 0.000 claims 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 230000003287 optical Effects 0.000 claims 1
- 229960000797 oxitropium Drugs 0.000 claims 1
- 229960004633 pirenzepine Drugs 0.000 claims 1
- 230000003389 potentiating Effects 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 229940021597 salmeterol and fluticasone Drugs 0.000 claims 1
- 229960002646 scopolamine Drugs 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- 229960004791 tropicamide Drugs 0.000 claims 1
Claims (24)
- 定量噴霧式吸入器から送達できる共懸濁剤であって、前記安定な共懸濁剤は
薬学的に許容できるＨＦＡ噴射剤を含み追加の構成成分を含まない懸濁媒体と、
複数の結晶活性剤粒子と、
複数の呼吸可能な懸濁粒子とを含み、
前記複数の懸濁粒子は懸濁媒体に実質的に不溶性であり、乾燥粒子リン酸物質を含み、懸濁媒体中の活性剤粒子と懸濁剤粒子との浮力差にもかかわらず活性剤粒子と同一場所に位置する
共懸濁剤。 - 前記複数の結晶活性剤粒子が、２つ以上の異なる結晶活性剤を含む、請求項１に記載の共懸濁剤。
- 前記結晶活性剤粒子が、ホルモテロール、サルメテロール、ベクロメタゾン、ブデソニド、シクレソニド、フルニソリド、フルチカゾン、メチルプレドニゾロン、モメタゾン、プレドニゾン、トリアムシノロン、エフェドリン、アドレナリン、フェノテロール、ホルモテロール、イソプレナリン、メタプロテレノール、サルブタモール、アルブテロール、サルメテロール、テルブタリン、グリコピロレート、デキシピロニウム、スコポラミン、トロピカミド、ピレンゼピン、ジメンヒドリネート、チオトロピウム、ダロトロピウム、アクリジニウム、トロスピウム、イプラトロピウム、アトロピン、ベンズトロピンおよびオキシトロピウム（その任意の薬学的に許容できる塩、エステル、異性体または溶媒和物を包含する）から選択される、請求項１または２に記載の共懸濁剤。
- 前記結晶活性剤粒子中に２つ以上の結晶活性剤が含まれ、前記２つ以上の活性剤が、ホルモテロールとブデソニドとの組合せ、グリコピロレートとホルモテロールとの組合せ、シクレソニドとホルモテロールとの組合せ、サルメテロールとフルチカゾンとの組合せ、グリコピロレートとホルモテロールとブデソニドとの組合せ、およびグリコピロレートとホルモテロールとモメタゾンとの組合せ（その任意の薬学的に許容できる塩、エステル、異性体または溶媒和物を包含する）から選択される、請求項１から３のいずれかに記載の共懸濁剤。
- 前記懸濁粒子が、０．５μｍ〜１５μｍの光学直径体積中央値を呈する、請求項１から４のいずれかに記載の共懸濁剤。
- 前記懸濁粒子が、３０ｍｇ／ｍＬまでおよび２５ｍｇ／ｍＬまでから選択される濃度で前記懸濁媒体中に含まれる、請求項１から５のいずれかに記載の共懸濁剤。
- 前記懸濁粒子が、１ｍｇ／ｍｌ〜１５ｍｇ／ｍｌ、３ｍｇ／ｍｌ〜１０ｍｇ／ｍｌ、１．５ｍｇ／ｍｌ〜１０ｍｇ／ｍｌから選択される濃度で前記懸濁媒体中に含まれる、請求項６に記載の共懸濁剤。
- 前記結晶活性剤粒子がグリコピロレートを含み、前記懸濁粒子が、６ｍｇ／ｍＬ、３ｍｇ／ｍＬ〜１０ｍｇ／ｍＬ、および１ｍｇ／ｍＬ〜１５ｍｇ／ｍＬから選択される濃度で前記懸濁媒体中に含まれる、請求項６に記載の共懸濁剤。
- 前記結晶活性剤粒子がホルモテロールを含み、前記懸濁粒子が、３ｍｇ／ｍＬ、１．５ｍｇ／ｍＬ〜５ｍｇ／ｍＬ、および０．５ｍｇ／ｍＬ〜７．５ｍｇ／ｍＬから選択される濃度で前記懸濁媒体中に含まれる、請求項６に記載の共懸濁剤。
- 前記結晶活性剤粒子がホルモテロールを含み、前記懸濁粒子が、６ｍｇ／ｍＬ、３ｍｇ／ｍＬ〜１０ｍｇ／ｍＬ、および１ｍｇ／ｍＬ〜１５ｍｇ／ｍＬから選択される濃度で前記懸濁媒体中に含まれる、請求項６に記載の共懸濁剤。
- 前記懸濁粒子の全質量が前記結晶活性剤粒子の全質量を超え、前記結晶活性剤粒子中に含まれる前記活性剤のうち少なくとも１つが高度に強力な活性剤であり、前記懸濁粒子の全質量対前記活性剤粒子の全質量の比率が、１０〜１５０、１５〜１２５、および２５〜７５から選択される、請求項１から１０のいずれかに記載の共懸濁剤。
- 前記活性剤粒子が、コルチコステロイドを含み、前記懸濁粒子の全質量対前記活性剤粒子の全質量の比率が、１〜２０、５〜１５、および１０から選択される、請求項１１に記載の共懸濁剤。
- コルチコステロイドは、フルチカゾン、モメタゾンおよびブデソニドのうち１つまたは複数から選択される、請求項１２に記載の共懸濁剤。
- 前記活性剤粒子がホルモテロールを含み、前記懸濁粒子の全質量対前記結晶活性剤粒子の全質量の比率が、１０〜２００、５０〜１２５、および７５から選択される、請求項１から１０のいずれかに記載の共懸濁剤。
- 前記懸濁粒子が、少なくとも１ｇ、少なくとも１０ｇ、少なくとも５０ｇおよび少なくとも１００ｇの加速度から選択される加速度での遠心分離により増幅された浮力を受けたときでも結晶活性剤粒子と同一場所にある、請求項１から１４のいずれかに記載の共懸濁剤。
- 計量体積を分配するための作動装置を備える出口バルブの付いた缶を具備し、前記缶が請求項１から１５のいずれかに記載の共懸濁剤を含有する定量噴霧式吸入器であって、前記缶が空になるまで、±３０％またはより良好な送達用量均一性（「ＤＤＵ」）、±２５％またはより良好なＤＤＵ、および±２０％またはより良好なＤＤＵから選択される、前記共懸濁製剤についてのＤＤＵを呈する定量噴霧式吸入器。
- 前記共懸濁剤を最初の微細粒子分率で分配し、前記定量噴霧式吸入器から分配される前記最初の微細粒子分率が、前記缶が空になるまで、前記定量噴霧式吸入器から送達される前記微細粒子分率が前記最初の微細粒子分率の８０％以内、最初の微細粒子分率の９０％以内または最初の微細粒子分率の９５％以内に維持されるように実質的に維持される、請求項１６に記載の定量噴霧式吸入器。
- 前記定量噴霧式吸入器の前記缶内に含有される前記共懸濁製剤が、少なくとも６カ月間保管安定性がある、請求項１６または１７に記載の定量噴霧式吸入器。
- 前記缶を６週間の期間にわたり６時間ごとに−５℃と４０℃の温度に交互にさらした後、前記缶が空になるまで、±３０％またはより良好な送達用量均一性（「ＤＤＵ」）、±２５％またはより良好なＤＤＵ、および±２０％またはより良好なＤＤＵから選択される前記共懸濁製剤についてのＤＤＵを呈する、請求項１６に記載の定量噴霧式吸入器。
- 前記微細粒子分率が、前記缶を６週間の期間にわたり６時間ごとに−５℃と４０℃の温度に交互にさらした後、前記缶が空になるまで実質的に維持される、請求項１７に記載の定量噴霧式吸入器。
- 炎症性または閉塞性の肺の疾患または状態に罹患している患者の治療用に調製されている、請求項１−１５のいずれかに記載の共懸濁剤。
- 疾患または状態は、喘息、ＣＯＰＤ、他の薬物療法の結果生じる気道過反応性の増悪、アレルギー性鼻炎、副鼻腔炎、肺血管収縮、炎症、アレルギー、呼吸障害、呼吸窮迫症候群、肺高血圧症、肺血管収縮、および嚢胞性線維症に伴う肺の炎症および閉塞から選択される、請求項２１に記載の共懸濁剤。
- 炎症性または閉塞性の肺の疾患または状態に罹患している患者の治療用に調製されている、請求項１６−２０のいずれかに記載の定量噴霧式吸入器。
- 疾患または状態は、喘息、ＣＯＰＤ、他の薬物療法の結果生じる気道過反応性の増悪、アレルギー性鼻炎、副鼻腔炎、肺血管収縮、炎症、アレルギー、呼吸障害、呼吸窮迫症候群、肺高血圧症、肺血管収縮、および嚢胞性線維症に伴う肺の炎症および閉塞から選択される、請求項２３に記載の定量噴霧式吸入器。
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18256509P | 2009-05-29 | 2009-05-29 | |
| US61/182,565 | 2009-05-29 | ||
| US25817209P | 2009-11-04 | 2009-11-04 | |
| US61/258,172 | 2009-11-04 | ||
| US30936510P | 2010-03-01 | 2010-03-01 | |
| US61/309,365 | 2010-03-01 | ||
| US34553610P | 2010-05-17 | 2010-05-17 | |
| US61/345,536 | 2010-05-17 | ||
| PCT/US2010/036650 WO2010138862A2 (en) | 2009-05-29 | 2010-05-28 | Compositions for respiratory delivery of active agents and associated methods and systems |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015084226A Division JP6169639B2 (ja) | 2009-05-29 | 2015-04-16 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012528199A JP2012528199A (ja) | 2012-11-12 |
| JP2012528199A5 true JP2012528199A5 (ja) | 2013-07-18 |
| JP5873012B2 JP5873012B2 (ja) | 2016-03-01 |
Family
ID=42269864
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513314A Active JP5823383B2 (ja) | 2009-05-29 | 2010-05-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2012513319A Active JP5873013B2 (ja) | 2009-05-29 | 2010-05-28 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2012513311A Active JP5873012B2 (ja) | 2009-05-29 | 2010-05-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2015084226A Active JP6169639B2 (ja) | 2009-05-29 | 2015-04-16 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2015084240A Active JP6189356B2 (ja) | 2009-05-29 | 2015-04-16 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015199079A Withdrawn JP2016041713A (ja) | 2009-05-29 | 2015-10-07 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2017125969A Active JP6492124B2 (ja) | 2009-05-29 | 2017-06-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2017149555A Active JP6348645B2 (ja) | 2009-05-29 | 2017-08-02 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2017188628A Pending JP2018048150A (ja) | 2009-05-29 | 2017-09-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2019038501A Active JP6876734B2 (ja) | 2009-05-29 | 2019-03-04 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513314A Active JP5823383B2 (ja) | 2009-05-29 | 2010-05-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2012513319A Active JP5873013B2 (ja) | 2009-05-29 | 2010-05-28 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015084226A Active JP6169639B2 (ja) | 2009-05-29 | 2015-04-16 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2015084240A Active JP6189356B2 (ja) | 2009-05-29 | 2015-04-16 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015199079A Withdrawn JP2016041713A (ja) | 2009-05-29 | 2015-10-07 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2017125969A Active JP6492124B2 (ja) | 2009-05-29 | 2017-06-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2017149555A Active JP6348645B2 (ja) | 2009-05-29 | 2017-08-02 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2017188628A Pending JP2018048150A (ja) | 2009-05-29 | 2017-09-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2019038501A Active JP6876734B2 (ja) | 2009-05-29 | 2019-03-04 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
Country Status (32)
| Country | Link |
|---|---|
| US (12) | US9463161B2 (ja) |
| EP (6) | EP3111926B1 (ja) |
| JP (10) | JP5823383B2 (ja) |
| KR (7) | KR101748892B1 (ja) |
| CN (6) | CN107412212B (ja) |
| AR (3) | AR076807A1 (ja) |
| AU (3) | AU2010253776B2 (ja) |
| BR (3) | BRPI1011508A2 (ja) |
| CA (3) | CA2763939A1 (ja) |
| CY (8) | CY1118040T1 (ja) |
| DK (6) | DK3111927T3 (ja) |
| ES (6) | ES2774391T3 (ja) |
| FR (1) | FR19C1040I2 (ja) |
| HK (6) | HK1169026A1 (ja) |
| HR (6) | HRP20161098T1 (ja) |
| HU (8) | HUE047803T2 (ja) |
| IL (3) | IL216466B (ja) |
| LT (8) | LT3106149T (ja) |
| LU (2) | LUC00124I2 (ja) |
| ME (1) | ME03631B (ja) |
| MX (4) | MX337126B (ja) |
| NL (1) | NL300995I2 (ja) |
| NO (2) | NO2019026I1 (ja) |
| PH (1) | PH12017500778A1 (ja) |
| PL (6) | PL3106149T3 (ja) |
| PT (6) | PT3111927T (ja) |
| RU (5) | RU2751771C2 (ja) |
| SI (6) | SI2435024T1 (ja) |
| SM (6) | SMT202000077T1 (ja) |
| TW (9) | TWI792140B (ja) |
| WO (3) | WO2010138884A2 (ja) |
| ZA (4) | ZA201108275B (ja) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1894591B1 (en) | 2002-03-20 | 2013-06-26 | MannKind Corporation | Cartridge for an inhalation apparatus |
| EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
| CN101027057B (zh) | 2004-08-23 | 2017-04-12 | 曼金德公司 | 用于药物输送的二酮哌嗪盐、二酮吗啉盐或二酮二氧杂环己烷盐 |
| US10002325B2 (en) | 2005-03-30 | 2018-06-19 | Primal Fusion Inc. | Knowledge representation systems and methods incorporating inference rules |
| DK1937219T3 (en) | 2005-09-14 | 2016-02-15 | Mannkind Corp | A method for drug formulation based on increasing the affinity of the crystalline surfaces of the microparticle of active principles |
| IN2015DN00888A (ja) | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
| WO2011163272A1 (en) * | 2010-06-21 | 2011-12-29 | Mannkind Corporation | Dry powder drug delivery system and methods |
| AU2009257311B2 (en) | 2008-06-13 | 2014-12-04 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CN102065942B (zh) | 2008-06-20 | 2013-12-11 | 曼金德公司 | 用于对吸入工作进行实时描绘的交互式设备和方法 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| CN107412212B (zh) * | 2009-05-29 | 2021-01-22 | 珍珠治疗公司 | 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统 |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| US10474647B2 (en) | 2010-06-22 | 2019-11-12 | Primal Fusion Inc. | Methods and devices for customizing knowledge representation systems |
| JP6133270B2 (ja) | 2011-04-01 | 2017-05-24 | マンカインド コーポレイション | 薬剤カートリッジのためのブリスター包装 |
| SG194896A1 (en) * | 2011-05-17 | 2013-12-30 | Pearl Therapeutics Inc | Compositions, methods & systems for respiratory delivery of two or more active agents |
| CN105106200A (zh) * | 2011-05-17 | 2015-12-02 | 珍珠治疗公司 | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| GB201113662D0 (en) * | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
| EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
| RU2666963C2 (ru) * | 2012-04-13 | 2018-09-13 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Агрегированные частицы |
| KR102264177B1 (ko) | 2012-07-12 | 2021-06-11 | 맨카인드 코포레이션 | 건조 분말 약물 전달 시스템 및 방법 |
| CN102872027B (zh) * | 2012-09-18 | 2014-03-12 | 刘晓忠 | 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备 |
| CN110464724A (zh) * | 2013-01-28 | 2019-11-19 | 理森制药股份公司 | 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法 |
| WO2014118532A1 (en) | 2013-01-31 | 2014-08-07 | Prosonix Limited | Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy |
| GB201301721D0 (en) * | 2013-01-31 | 2013-03-20 | Prosonix Ltd | Pharmaceutical Preparations |
| CN105307639B (zh) * | 2013-03-04 | 2020-06-30 | 博赏医药卢森堡责任有限公司 | 包含与载体颗粒结合的活性剂纳米颗粒的干药物组合物 |
| MX2015012529A (es) * | 2013-03-14 | 2016-07-05 | Novartis Ag | Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla. |
| SG11201507286QA (en) * | 2013-03-15 | 2015-10-29 | Pearl Therapeutics Inc | Methods and systems for conditioning of particulate crystalline materials |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| JP6473738B2 (ja) | 2013-04-01 | 2019-02-20 | パルマトリックス，インコーポレイテッド | チオトロピウム乾燥粉末 |
| US9393202B2 (en) * | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| WO2014190204A1 (en) * | 2013-05-22 | 2014-11-27 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of three or more active agents |
| KR102465025B1 (ko) | 2013-07-18 | 2022-11-09 | 맨카인드 코포레이션 | 열-안정성 건조 분말 약제학적 조성물 및 방법 |
| PT3054920T (pt) * | 2013-10-07 | 2021-03-23 | Teva Branded Pharmaceutical Products R&D Inc | Inalador de pó seco |
| KR20160101928A (ko) * | 2013-11-22 | 2016-08-26 | 테바 브랜디드 파마슈티컬 프로덕츠 알앤디, 인코포레이티드 | 흡입 약제 |
| GB201321717D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| GB201402556D0 (en) | 2014-02-13 | 2014-04-02 | Crystec Ltd | Improvements relating to inhalable particles |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| CN104188941B (zh) * | 2014-09-02 | 2016-11-16 | 重庆和平制药有限公司 | 一种制备盐酸克仑特罗吸入粉雾剂的方法 |
| MX2017004322A (es) * | 2014-10-01 | 2017-08-28 | Als Mountain Llc | Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico. |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| WO2016170518A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| TW201735914A (zh) | 2015-12-22 | 2017-10-16 | 阿斯特捷利康公司 | 用於治療慢性阻塞性肺疾病之醫藥組成物 |
| WO2017157265A1 (zh) * | 2016-03-15 | 2017-09-21 | 广东东阳光药业有限公司 | 喷雾剂、喷雾装置以及喷雾组件 |
| WO2017201003A1 (en) * | 2016-05-17 | 2017-11-23 | Mayo Foundation For Medical Education And Research | Materials and methods for treating chronic cough |
| MX2018015119A (es) | 2016-06-30 | 2019-04-15 | Philip Morris Products Sa | Particulas de nicotina. |
| AU2017328907B2 (en) | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| JP6906947B2 (ja) * | 2016-12-22 | 2021-07-21 | キヤノン株式会社 | 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| CN107243080B (zh) * | 2017-06-21 | 2021-11-12 | 上海上药信谊药厂有限公司 | 一种吸入式气雾剂、其原料组合物及制备方法 |
| ES2970740T3 (es) * | 2017-10-09 | 2024-05-30 | Pearl Therapeutics Inc | Unidad de administración de aerosol |
| JP7372727B2 (ja) | 2017-11-20 | 2023-11-01 | 三菱重工業株式会社 | 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム |
| EP3861988A4 (en) * | 2018-10-02 | 2022-06-29 | Meijo University Educational Foundation | Powder inhaler, method for assessing same, and use of same |
| CN109632555B (zh) * | 2018-12-28 | 2021-07-27 | 上海新黄河制药有限公司 | 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法 |
| WO2020229966A1 (en) * | 2019-05-10 | 2020-11-19 | Glenmark Pharmaceutical Limited | Stable aerosol composition for inhalation comprising glycopyrronium |
| CN112137957B (zh) | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| WO2020263994A1 (en) * | 2019-06-27 | 2020-12-30 | Cai Gu Huang | Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide |
| CN112972384B (zh) * | 2019-12-02 | 2022-03-18 | 长风药业股份有限公司 | 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法 |
| IL295269A (en) * | 2020-02-20 | 2022-10-01 | Chiesi Farm Spa | Inhalers with a measured dose under pressure that include the composition of pharmacy buffers |
| PE20230382A1 (es) * | 2020-05-18 | 2023-03-06 | Orexo Ab | Nueva composicion farmaceutica para administracion de farmacos |
| US20220000767A1 (en) * | 2020-07-06 | 2022-01-06 | Sensory Cloud, Inc. | Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi |
| WO2022016068A1 (en) * | 2020-07-16 | 2022-01-20 | Tbd Pharma Llc | Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections |
| WO2022148418A1 (zh) * | 2021-01-08 | 2022-07-14 | 江苏恒瑞医药股份有限公司 | 可通过定量吸入器递送的药物组合物 |
| JP2024049405A (ja) * | 2021-02-22 | 2024-04-10 | 興和株式会社 | 新規吸入剤 |
| US20240252432A1 (en) | 2021-07-09 | 2024-08-01 | Astrazeneca Pharmaceuticals Lp | Compositions, methods and systems for aerosol drug delivery |
| AU2022395920A1 (en) | 2021-11-25 | 2024-05-30 | Orexo Ab | Pharmaceutical composition comprising adrenaline |
| EP4452230A1 (en) | 2021-12-20 | 2024-10-30 | Astrazeneca AB | Compositions, methods and systems for aerosol drug delivery |
| WO2023212191A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Combination of albuterol and budesonide for the treatment of asthma |
| WO2024206662A1 (en) * | 2023-03-30 | 2024-10-03 | Aerorx Therapeutics Llc | Liquid formulations of indacaterol and glycopyrronium |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
| CN118787617A (zh) * | 2024-09-14 | 2024-10-18 | 苏州易合医药有限公司 | 一种吸入粉剂及其制备方法 |
Family Cites Families (176)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| SE378109B (ja) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US4187301A (en) * | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
| ZA81976B (en) * | 1980-02-15 | 1982-07-28 | Glaxo Group Ltd | Androstane carbothioates |
| EP0057401B1 (en) * | 1981-02-02 | 1984-08-01 | Schering Corporation | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| GB8432063D0 (en) | 1984-12-19 | 1985-01-30 | Riker Laboratories Inc | Physically modified steroids |
| US5707634A (en) * | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| GB8903593D0 (en) * | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| DE69002718T2 (de) | 1989-09-08 | 1993-12-23 | Glaxo Group Ltd | Medikamente. |
| IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US5610163A (en) * | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| IE912999A1 (en) | 1990-09-07 | 1992-03-11 | Abbott Lab | Phenanthridine compounds |
| ATE113604T1 (de) | 1990-09-10 | 1994-11-15 | Schering Corp | Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen. |
| DE4108393A1 (de) | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
| US5635563A (en) | 1991-04-01 | 1997-06-03 | Tomoegawa Paper Co., Ltd. | Polyaniline derivatives and their production process |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
| CZ288032B6 (cs) | 1991-12-18 | 2001-04-11 | Aktiebolaget Astra | Farmaceutický prostředek pro podání inhalací |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US5849263A (en) | 1993-03-30 | 1998-12-15 | Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions containing alkylaryl polyether alcohol polymer |
| GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| EP0731688B1 (en) | 1993-12-02 | 2003-03-05 | Abbott Laboratories | Aerosol drug formulations for use with non-cfc propellants |
| SE9404080L (sv) * | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| NZ279549A (en) * | 1994-02-09 | 1996-11-26 | Kinerton Ltd | Obtaining solid material by drying a solution thereof, supercooled spray of solution expanded into vacuum and frozen droplets collected |
| GB9413202D0 (en) * | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| HUT77775A (hu) | 1994-12-22 | 1998-08-28 | Astra Aktiebolag | Aeroszolformák |
| US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| GB9507768D0 (en) | 1995-04-13 | 1995-05-31 | Glaxo Group Ltd | Method of apparatus |
| CA2218074C (en) * | 1995-04-14 | 2002-10-08 | Mohammed Eljamal | Powdered pharmaceutical formulations having improved dispersibility |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US6309671B1 (en) * | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| DE19614421C2 (de) | 1996-04-12 | 1999-12-16 | Biovision Gmbh | Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff |
| GB9610821D0 (en) | 1996-05-23 | 1996-07-31 | Glaxo Wellcome Inc | Metering apparatus |
| US6054488A (en) * | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
| GB9612297D0 (en) * | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| US5886200A (en) * | 1996-07-01 | 1999-03-23 | Schering Corporation | Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones |
| US6068832A (en) * | 1996-08-29 | 2000-05-30 | Schering Corporation | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
| SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| SI0937041T1 (en) * | 1996-11-11 | 2003-10-31 | Christian R. Noe | Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| EP0969816B1 (en) | 1997-03-20 | 2004-12-15 | Schering Corporation | Preparation of powder agglomerates |
| US6129905A (en) * | 1997-04-21 | 2000-10-10 | Aeropharm Technology, Inc. | Aerosol formulations containing a sugar as a dispersant |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6946117B1 (en) * | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| CA2304973C (en) | 1997-09-29 | 2009-11-17 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in nebulizers |
| US6433040B1 (en) * | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6423691B1 (en) | 1998-03-05 | 2002-07-23 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytography |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| US6260549B1 (en) * | 1998-06-18 | 2001-07-17 | Clavius Devices, Inc. | Breath-activated metered-dose inhaler |
| US6451285B2 (en) * | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| NZ509328A (en) | 1998-07-24 | 2002-11-26 | Jago Res A | Medicinal aerosol formulations |
| NZ509489A (en) * | 1998-08-04 | 2002-10-25 | Jago Res A | Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil |
| EP1283036B2 (de) * | 1998-11-13 | 2020-01-01 | Jagotec AG | Multidosis-Trockenpulverinhalator mit Pulverreservoir |
| GB9912639D0 (en) * | 1999-05-28 | 1999-07-28 | Britannia Pharmaceuticals Ltd | Improvements in and relating to treatment of respiratory conditions |
| GB9826284D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| KR20010099865A (ko) | 1998-12-22 | 2001-11-09 | 프란시스 제이 메이어 | 기도 질병 치료용 화합물과 그의 치료 방법 및 기도약물의 전달 방법 |
| GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9904919D0 (en) * | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| ATE363892T1 (de) | 1999-03-05 | 2007-06-15 | Chiesi Farma Spa | Verbesserte pulverformulierungen zur inhalation |
| SE9900833D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| AU4417500A (en) | 1999-04-14 | 2000-11-14 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
| US20100197719A1 (en) * | 1999-05-12 | 2010-08-05 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| EP1196236B1 (en) | 1999-06-30 | 2007-08-29 | Nektar Therapeutics | Spray drying process and system for preparing dry powders |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| PT102343B (pt) * | 1999-08-02 | 2003-11-28 | Hovione Farmaciencia Sa | Processo para a preparacao de furoato mometasona |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| DE60044070D1 (de) * | 1999-10-29 | 2010-05-06 | Novartis Ag | Trockenpulverzusammensetzungen mit verbesserter Dispersität |
| DE19961300A1 (de) * | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| EP1274433A1 (en) | 2000-04-13 | 2003-01-15 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| TWI290473B (en) * | 2000-05-10 | 2007-12-01 | Alliance Pharma | Phospholipid-based powders for drug delivery |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| AU2000265583A1 (en) | 2000-08-15 | 2002-02-25 | Carsten Berg | Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides |
| FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| US20040081627A1 (en) * | 2000-10-09 | 2004-04-29 | Jinks Phillip A | Medicinal aerosol formulations |
| US6908928B2 (en) * | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| ATE517607T1 (de) | 2000-11-30 | 2011-08-15 | Vectura Ltd | Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung |
| CA2429665C (en) * | 2000-11-30 | 2013-10-22 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| GB0029562D0 (en) | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
| US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| CA2433335C (en) | 2000-12-29 | 2010-04-20 | Advanced Inhalation Research, Inc. | Particles for inhalation having sustained release properties |
| ITMI20010428A1 (it) * | 2001-03-02 | 2002-09-02 | Chemo Breath S A | Composizioni ad uso inalatorio a base di formoterolo |
| IL157580A0 (en) * | 2001-03-20 | 2004-03-28 | Glaxo Group Ltd | Inhalation drug combination |
| EP1372608B1 (de) * | 2001-03-30 | 2007-10-10 | Jagotec Ag | Medizinische aerosolformulierungen |
| WO2002078761A1 (fr) * | 2001-03-30 | 2002-10-10 | Laboratoires Genevrier | Neo-tissu cartilagineux greffable |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| TWI324934B (en) * | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| DE10202940A1 (de) * | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| DE10214264A1 (de) * | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA-Suspensionsformulierungen eines Anhydrats |
| US7244415B2 (en) | 2002-03-28 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations of an anhydrate |
| GB0207906D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| DE10216429A1 (de) | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
| CA2487399A1 (en) * | 2002-06-12 | 2004-02-19 | Epigenesis Pharmaceuticals, Inc. | Combination of anti-muscarinic agents and non-glucocorticoid steroids |
| US7244742B2 (en) * | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
| DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| AU2003259986A1 (en) | 2002-08-23 | 2004-03-11 | Schering Corporation | Pharmaceutical compositions |
| JP2006503865A (ja) | 2002-09-30 | 2006-02-02 | アキュスフィア， インコーポレイテッド | 吸入のための徐放性の多孔性微粒子 |
| CA2499099C (en) * | 2002-10-15 | 2009-01-20 | Cryovac, Inc. | A process for triggering, storing, and distributing an oxygen scavenger, and a stored oxygen scavenger |
| EP1452179A1 (en) | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| DE10323966A1 (de) | 2003-05-27 | 2004-12-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
| WO2005000267A2 (en) | 2003-05-28 | 2005-01-06 | Nektar Therapeutics | Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat |
| EP1638567B1 (en) * | 2003-06-16 | 2012-02-29 | Nycomed GmbH | Composition comprising a pulmonary surfactant and sildenafil for the treatment of lung diseases |
| SE527190C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
| EP1651221B1 (en) | 2003-07-28 | 2009-01-14 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising betamimetics and an anticholinergic agent |
| BRPI0413054A (pt) | 2003-07-29 | 2006-10-17 | Boehringer Ingelheim Int | combinação de um anticolinérgico e um esteróide e seu uso no tratamento de distúrbios respiratórios por inalação |
| SI1651270T1 (sl) | 2003-07-29 | 2007-08-31 | Boehringer Ingelheim Int | Zdravila za inhalacijo, ki obsegajo betamimetike in antiholinergik |
| CA2534120C (en) | 2003-07-31 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising anticholinergics and a betamimetic |
| EP1925293A3 (en) | 2003-10-20 | 2010-01-13 | Schering Corporation | Pharmaceutical aerosol compositions |
| US9308199B2 (en) | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
| DE602004021959D1 (de) * | 2003-11-21 | 2009-08-20 | Theravance Inc | Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor |
| SE0303270L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
| JP2007517068A (ja) | 2003-12-31 | 2007-06-28 | サイデックス・インコーポレイテッド | 単位用量懸濁液から調製されるスルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤 |
| WO2005074900A2 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES |
| PT1713473E (pt) | 2004-02-06 | 2013-05-13 | Meda Pharma Gmbh & Co Kg | Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd |
| US20050287077A1 (en) * | 2004-02-10 | 2005-12-29 | James E. Shipley | Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon |
| GB0411056D0 (en) * | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| RU2389477C2 (ru) * | 2004-06-18 | 2010-05-20 | Новартис Ваксинз Энд Дайагностикс Инк. | Способы лечения эндобронхиальных заболеваний |
| GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
| US20060140873A1 (en) | 2004-12-27 | 2006-06-29 | Chang Heng W | Aerosol pharmaceutical compositions |
| JP2008534480A (ja) | 2005-03-24 | 2008-08-28 | ソーセイ アールアンドディ リミテッド | グリコピロニウム塩およびそれらの治療的使用 |
| WO2006105401A2 (en) * | 2005-03-30 | 2006-10-05 | Schering Corporation | Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist |
| WO2006114379A1 (de) | 2005-04-23 | 2006-11-02 | Boehringer Ingelheim International Gmbh | Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| WO2006128847A2 (en) | 2005-05-31 | 2006-12-07 | Boehringer Ingelheim International Gmbh | Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor |
| JP2008543806A (ja) | 2005-06-17 | 2008-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療のためのｍｒｐｉｖインヒビター |
| EP1904219A4 (en) | 2005-07-15 | 2011-07-27 | Map Pharmaceuticals Inc | METHOD FOR FORMING PARTICLES |
| WO2007011989A2 (en) | 2005-07-15 | 2007-01-25 | Map Pharmaceuticals, Inc. | Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof |
| CN100560598C (zh) | 2005-07-26 | 2009-11-18 | 上海奥锐特国际贸易有限公司 | 氟替卡松丙酸酯的合成方法 |
| AT502396B1 (de) | 2005-09-01 | 2007-03-15 | Montanuniv Leoben | Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| SI1971369T1 (sl) | 2005-12-21 | 2009-12-31 | Meda Pharma Gmbh & Co Kg | Kombinacija R,R-glikopirolata,roliprama in budezonida za zdravljenje vnetnih bolezni |
| US8263645B2 (en) * | 2006-02-03 | 2012-09-11 | Pari Pharma Gmbh | Disodium cromoglycate compositions and methods for administering same |
| US20070202055A1 (en) * | 2006-02-09 | 2007-08-30 | Julianne Berry | Pharmaceutical Formulations |
| JP2009537585A (ja) | 2006-05-24 | 2009-10-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療のための新規医薬組成物 |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0614621D0 (en) * | 2006-07-24 | 2006-08-30 | 3M Innovative Properties Co | Metered dose dispensers |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| EP2124915A2 (en) * | 2007-02-19 | 2009-12-02 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
| EP1964564A1 (en) * | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
| EP2036572A1 (en) | 2007-09-04 | 2009-03-18 | Novo Nordisk A/S | Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle |
| CN101317821B (zh) * | 2007-11-15 | 2012-01-04 | 陈晓东 | 适用于肺部给药的超细干粉颗粒及其制备方法 |
| CN101896162B (zh) * | 2007-12-13 | 2013-06-05 | 诺瓦提斯公司 | 有机化合物 |
| GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| FR2940162B1 (fr) | 2008-12-22 | 2011-02-25 | Boehm & Cie Ets | Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension |
| WO2010097188A1 (en) | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a salt of carmoterol and a corticosteroid |
| CN107412212B (zh) * | 2009-05-29 | 2021-01-22 | 珍珠治疗公司 | 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统 |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| WO2011120779A1 (en) | 2010-04-01 | 2011-10-06 | Chiesi Farmaceutici S.P.A. | Process for preparing carrier particles for dry powders for inhalation |
| EP2627317A4 (en) | 2010-10-15 | 2014-08-20 | Glaxo Group Ltd | MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE |
| EP2749277A3 (en) | 2011-02-17 | 2014-08-27 | Cipla Limited | Combination of glycopyrronium and vilanterol |
| JO3510B1 (ar) | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
| SG194896A1 (en) | 2011-05-17 | 2013-12-30 | Pearl Therapeutics Inc | Compositions, methods & systems for respiratory delivery of two or more active agents |
| WO2014190204A1 (en) | 2013-05-22 | 2014-11-27 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of three or more active agents |
-
2010
- 2010-05-28 CN CN201610862606.5A patent/CN107412212B/zh active Active
- 2010-05-28 LT LTEP16164845.6T patent/LT3106149T/lt unknown
- 2010-05-28 KR KR1020117028551A patent/KR101748892B1/ko active IP Right Grant
- 2010-05-28 HU HUE16164844A patent/HUE047803T2/hu unknown
- 2010-05-28 ES ES16164844T patent/ES2774391T3/es active Active
- 2010-05-28 EP EP16164844.9A patent/EP3111926B1/en active Active
- 2010-05-28 LT LTEP10721258.1T patent/LT2435023T/lt unknown
- 2010-05-28 PT PT161648498T patent/PT3111927T/pt unknown
- 2010-05-28 TW TW110100317A patent/TWI792140B/zh active
- 2010-05-28 CN CN201510450391.1A patent/CN105193773B/zh active Active
- 2010-05-28 PL PL16164845T patent/PL3106149T3/pl unknown
- 2010-05-28 SM SM20200077T patent/SMT202000077T1/it unknown
- 2010-05-28 LT LTEP16164849.8T patent/LT3111927T/lt unknown
- 2010-05-28 DK DK16164849.8T patent/DK3111927T3/da active
- 2010-05-28 ES ES10727553.9T patent/ES2593429T3/es active Active
- 2010-05-28 ES ES16164845T patent/ES2772253T3/es active Active
- 2010-05-28 WO PCT/US2010/036676 patent/WO2010138884A2/en active Application Filing
- 2010-05-28 PT PT107212581T patent/PT2435023T/pt unknown
- 2010-05-28 TW TW107143778A patent/TWI707700B/zh active
- 2010-05-28 HU HUE10727551A patent/HUE031229T2/en unknown
- 2010-05-28 ME MEP-2020-37A patent/ME03631B/me unknown
- 2010-05-28 KR KR1020117028582A patent/KR20120015334A/ko not_active Application Discontinuation
- 2010-05-28 KR KR1020197012625A patent/KR20190049943A/ko not_active Application Discontinuation
- 2010-05-28 TW TW105116641A patent/TWI633898B/zh active
- 2010-05-28 AU AU2010253776A patent/AU2010253776B2/en active Active
- 2010-05-28 ES ES16164849T patent/ES2774367T3/es active Active
- 2010-05-28 TW TW099117219A patent/TWI546094B/zh active
- 2010-05-28 PT PT107275539T patent/PT2435025T/pt unknown
- 2010-05-28 SI SI201031260A patent/SI2435024T1/sl unknown
- 2010-05-28 JP JP2012513314A patent/JP5823383B2/ja active Active
- 2010-05-28 JP JP2012513319A patent/JP5873013B2/ja active Active
- 2010-05-28 TW TW099117220A patent/TWI539979B/zh active
- 2010-05-28 RU RU2016107464A patent/RU2751771C2/ru active
- 2010-05-28 TW TW105111487A patent/TWI646980B/zh active
- 2010-05-28 ES ES10727551.3T patent/ES2589135T3/es active Active
- 2010-05-28 BR BRPI1011508A patent/BRPI1011508A2/pt not_active Application Discontinuation
- 2010-05-28 DK DK10727551.3T patent/DK2435024T3/en active
- 2010-05-28 EP EP10727553.9A patent/EP2435025B1/en active Active
- 2010-05-28 AR ARP100101884A patent/AR076807A1/es not_active Application Discontinuation
- 2010-05-28 KR KR1020187034755A patent/KR20180130602A/ko active IP Right Grant
- 2010-05-28 MX MX2011012783A patent/MX337126B/es active IP Right Grant
- 2010-05-28 HU HUE10727553A patent/HUE029532T2/en unknown
- 2010-05-28 DK DK10721258.1T patent/DK2435023T3/en active
- 2010-05-28 US US12/790,448 patent/US9463161B2/en active Active
- 2010-05-28 BR BRPI1011220-0A patent/BRPI1011220B1/pt active IP Right Grant
- 2010-05-28 SM SM20200108T patent/SMT202000108T1/it unknown
- 2010-05-28 SI SI201031984T patent/SI3111927T1/sl unknown
- 2010-05-28 DK DK10727553.9T patent/DK2435025T3/en active
- 2010-05-28 PT PT161648456T patent/PT3106149T/pt unknown
- 2010-05-28 EP EP16164845.6A patent/EP3106149B1/en active Active
- 2010-05-28 US US12/790,710 patent/US20110132357A1/en not_active Abandoned
- 2010-05-28 CA CA2763939A patent/CA2763939A1/en not_active Abandoned
- 2010-05-28 MX MX2011012685A patent/MX350164B/es active IP Right Grant
- 2010-05-28 EP EP10721258.1A patent/EP2435023B1/en active Active
- 2010-05-28 US US12/790,671 patent/US20110135737A1/en not_active Abandoned
- 2010-05-28 SM SM20200109T patent/SMT202000109T1/it unknown
- 2010-05-28 HU HUE10721258A patent/HUE031283T2/hu unknown
- 2010-05-28 US US12/790,605 patent/US8808713B2/en active Active
- 2010-05-28 TW TW106115156A patent/TWI717511B/zh active
- 2010-05-28 LT LTEP10727551.3T patent/LT2435024T/lt unknown
- 2010-05-28 LT LTEP10727553.9T patent/LT2435025T/lt unknown
- 2010-05-28 EP EP16164849.8A patent/EP3111927B1/en active Active
- 2010-05-28 PL PL10727551T patent/PL2435024T3/pl unknown
- 2010-05-28 CN CN201710722981.4A patent/CN107669664B/zh active Active
- 2010-05-28 SI SI201031262A patent/SI2435025T1/sl unknown
- 2010-05-28 PL PL16164849T patent/PL3111927T3/pl unknown
- 2010-05-28 CN CN201080033312.2A patent/CN102753152B/zh active Active
- 2010-05-28 PT PT161648449T patent/PT3111926T/pt unknown
- 2010-05-28 SI SI201031975T patent/SI3106149T1/sl unknown
- 2010-05-28 PL PL10727553T patent/PL2435025T3/pl unknown
- 2010-05-28 ES ES10721258.1T patent/ES2592536T3/es active Active
- 2010-05-28 AU AU2010253770A patent/AU2010253770B9/en active Active
- 2010-05-28 DK DK16164844.9T patent/DK3111926T3/da active
- 2010-05-28 AU AU2010253950A patent/AU2010253950C1/en active Active
- 2010-05-28 EP EP10727551.3A patent/EP2435024B1/en active Active
- 2010-05-28 DK DK16164845.6T patent/DK3106149T3/da active
- 2010-05-28 TW TW099117221A patent/TWI632926B/zh active
- 2010-05-28 TW TW107126090A patent/TWI695723B/zh active
- 2010-05-28 PT PT107275513T patent/PT2435024T/pt unknown
- 2010-05-28 WO PCT/US2010/036650 patent/WO2010138862A2/en active Application Filing
- 2010-05-28 BR BRPI1011229A patent/BRPI1011229B8/pt active IP Right Grant
- 2010-05-28 RU RU2011154083A patent/RU2580315C3/ru active Protection Beyond IP Right Term
- 2010-05-28 PL PL16164844T patent/PL3111926T3/pl unknown
- 2010-05-28 RU RU2016117972A patent/RU2016117972A/ru not_active Application Discontinuation
- 2010-05-28 CA CA2763936A patent/CA2763936C/en active Active
- 2010-05-28 CN CN201080033310.3A patent/CN102596176B/zh active Active
- 2010-05-28 JP JP2012513311A patent/JP5873012B2/ja active Active
- 2010-05-28 HU HUE16164845A patent/HUE047834T2/hu unknown
- 2010-05-28 KR KR1020177024590A patent/KR101926060B1/ko active IP Right Grant
- 2010-05-28 RU RU2015151358A patent/RU2713404C2/ru active
- 2010-05-28 SI SI201031985T patent/SI3111926T1/sl unknown
- 2010-05-28 SI SI201031263A patent/SI2435023T1/sl unknown
- 2010-05-28 PL PL10721258T patent/PL2435023T3/pl unknown
- 2010-05-28 AR ARP100101882A patent/AR076806A1/es not_active Application Discontinuation
- 2010-05-28 WO PCT/US2010/036659 patent/WO2010138868A2/en active Application Filing
- 2010-05-28 LT LTEP16164844.9T patent/LT3111926T/lt unknown
- 2010-05-28 KR KR1020117028583A patent/KR101976107B1/ko active IP Right Grant
- 2010-05-28 CN CN201080033311.8A patent/CN102458364B/zh active Active
- 2010-05-28 HU HUE16164849A patent/HUE047823T2/hu unknown
- 2010-05-28 MX MX2011012684A patent/MX350163B/es active IP Right Grant
- 2010-05-28 CA CA2763941A patent/CA2763941A1/en not_active Abandoned
- 2010-05-28 KR KR1020177016074A patent/KR20170070274A/ko not_active Application Discontinuation
- 2010-05-28 AR ARP100101885A patent/AR076621A1/es not_active Application Discontinuation
-
2011
- 2011-11-10 ZA ZA2011/08275A patent/ZA201108275B/en unknown
- 2011-11-20 IL IL216466A patent/IL216466B/en active IP Right Grant
- 2011-11-20 IL IL216467A patent/IL216467B/en active IP Right Grant
- 2011-11-20 IL IL216468A patent/IL216468B/en active IP Right Grant
- 2011-11-28 MX MX2020004077A patent/MX2020004077A/es unknown
-
2012
- 2012-10-03 HK HK12109725.9A patent/HK1169026A1/zh unknown
- 2012-10-03 HK HK12109728.6A patent/HK1169307A1/zh unknown
- 2012-10-03 HK HK12109730.2A patent/HK1169027A1/zh unknown
- 2012-10-26 ZA ZA2012/08100A patent/ZA201208100B/en unknown
- 2012-10-26 ZA ZA2012/08101A patent/ZA201208101B/en unknown
- 2012-10-26 ZA ZA2012/08102A patent/ZA201208102B/en unknown
-
2014
- 2014-07-09 US US14/327,425 patent/US20150017247A1/en not_active Abandoned
-
2015
- 2015-04-16 JP JP2015084226A patent/JP6169639B2/ja active Active
- 2015-04-16 JP JP2015084240A patent/JP6189356B2/ja active Active
- 2015-10-07 JP JP2015199079A patent/JP2016041713A/ja not_active Withdrawn
-
2016
- 2016-04-21 US US15/135,389 patent/US20170071850A1/en not_active Abandoned
- 2016-06-15 HK HK16106903.5A patent/HK1218867A1/zh unknown
- 2016-08-26 HR HRP20161098TT patent/HRP20161098T1/hr unknown
- 2016-08-26 HR HRP20161102TT patent/HRP20161102T1/hr unknown
- 2016-08-26 HR HRP20161101TT patent/HRP20161101T1/hr unknown
- 2016-08-30 US US15/252,001 patent/US20170112759A1/en not_active Abandoned
- 2016-09-20 SM SM201600327T patent/SMT201600327B/it unknown
- 2016-09-20 SM SM201600326T patent/SMT201600326B/it unknown
- 2016-09-21 SM SM201600329T patent/SMT201600329B/it unknown
- 2016-09-21 CY CY20161100939T patent/CY1118040T1/el unknown
- 2016-09-21 CY CY20161100940T patent/CY1118034T1/el unknown
- 2016-09-21 CY CY20161100941T patent/CY1118030T1/el unknown
-
2017
- 2017-04-26 PH PH12017500778A patent/PH12017500778A1/en unknown
- 2017-06-15 US US15/624,597 patent/US20180125776A1/en not_active Abandoned
- 2017-06-28 JP JP2017125969A patent/JP6492124B2/ja active Active
- 2017-08-02 JP JP2017149555A patent/JP6348645B2/ja active Active
- 2017-09-28 JP JP2017188628A patent/JP2018048150A/ja active Pending
-
2018
- 2018-02-16 US US15/932,249 patent/US20190038548A1/en not_active Abandoned
- 2018-03-14 HK HK18103575.7A patent/HK1244669A1/zh unknown
- 2018-05-21 HK HK18106607.2A patent/HK1247095A1/zh unknown
- 2018-11-02 US US16/179,712 patent/US10716753B2/en active Active
-
2019
- 2019-03-04 JP JP2019038501A patent/JP6876734B2/ja active Active
- 2019-06-06 CY CY2019031C patent/CY2019031I2/el unknown
- 2019-06-12 LU LU00124C patent/LUC00124I2/fr unknown
- 2019-06-12 FR FR19C1040C patent/FR19C1040I2/fr active Active
- 2019-06-12 HU HUS1900031C patent/HUS1900031I1/hu unknown
- 2019-06-13 NO NO2019026C patent/NO2019026I1/no unknown
- 2019-06-14 NL NL300995C patent/NL300995I2/nl unknown
- 2019-06-17 LT LTPA2019014C patent/LTC2435025I2/lt unknown
-
2020
- 2020-01-24 RU RU2020102859A patent/RU2020102859A/ru unknown
- 2020-01-31 HR HRP20200166TT patent/HRP20200166T1/hr unknown
- 2020-02-14 CY CY20201100136T patent/CY1122749T1/el unknown
- 2020-02-17 HR HRP20200260TT patent/HRP20200260T1/hr unknown
- 2020-02-21 HR HRP20200298TT patent/HRP20200298T1/hr unknown
- 2020-02-25 CY CY20201100173T patent/CY1122732T1/el unknown
- 2020-02-28 CY CY20201100185T patent/CY1122807T1/el unknown
- 2020-08-03 US US16/983,543 patent/US20210186861A1/en not_active Abandoned
-
2021
- 2021-05-10 CY CY2021012C patent/CY2021012I2/el unknown
- 2021-05-12 HU HUS2100018C patent/HUS2100018I1/hu unknown
- 2021-05-12 NO NO2021019C patent/NO2021019I1/no unknown
- 2021-05-19 LU LU00208C patent/LUC00208I2/fr unknown
- 2021-06-04 LT LTPA2021511C patent/LTC2435024I2/lt unknown
-
2024
- 2024-02-20 US US18/582,344 patent/US20250009652A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012528199A5 (ja) | ||
| JP2012528792A5 (ja) | ||
| JP6492124B2 (ja) | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 | |
| JP2012528200A5 (ja) | ||
| JP2016041713A5 (ja) | ||
| AU2010305695B2 (en) | Improved formulations | |
| CN101657191B (zh) | 包括福莫特罗和二丙酸倍氯米松的组合物在制备用于预防和/或治疗哮喘恶化的药物中的用途 | |
| JP2019182878A (ja) | 改善された医薬エアゾール製剤 | |
| US20130104881A1 (en) | Stabilized Metered Dose Inhaler | |
| US20160317391A1 (en) | Media milling process for the manufacture of active pharmaceutical ingredients in propellants | |
| TW202317080A (zh) | 用於氣溶膠遞送之組合物、方法及系統 | |
| AU2013203244B2 (en) | Improved formulations | |
| US20110182830A1 (en) | Inhalation drug products, systems and uses | |
| Linne-Geyer et al. | P291 In-use stability of aclidinium bromide 400 μg/formoterol fumarate dihydrate 12 μg inhalation powder in a dry powder inhaler | |
| BR102012027127A2 (pt) | Composição contida em um inalador farmacêutico pressurizado com medidores de dosagem |